Skip to main content
padlock icon - secure page this page is secure

Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?

Buy Article:

Price: $63.00 + tax (Refund Policy)

Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Metabolomics; biomarkers; endometriosis; gynecology; leiomyoma; ovarian neoplasms; polycystic ovary syndrome; uterine cervical neoplasms

Affiliations: 1: Institute of Perinatology and Pediatric, Almazov National Medical Research Centre, Saint-Petersburg 197341, Russia. 2: International Research Centre “Biotechnologies of the Third Millennium”, ITMO University, Saint-Petersburg 197341, Russia.

Appeared or available online: March 8, 2019

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more